RenJi Hospital: Carcinoma, Hepatocellular trials
The registry lists 17 Carcinoma, Hepatocellular studies with RenJi Hospital as lead sponsor. 5 are open to participants now and 0 have results posted.
Phase 1 1Phase 2 3Phase 3 3No phase 12(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- FGF19 Overexpression Combination Unified Study in HCC-19RecruitingNCT06978933Phase 2
- Prospective Real-World Study of HAIC With Raltitrexed or 5-Fluorouracil for the Treatment of Hepatocellular CarcinomaRecruitingNCT06519578Not applicable
- GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular CarcinomaRecruitingNCT05926726Not applicable
- Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )RecruitingNCT04443322Not applicable
- Lenvatinib Following Liver Transplantation in Patients of Hepatocellular Carcinoma With Portal Vein Tumor ThrombusNot yet recruitingNCT04319484Phase 2/3
- Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCCActive, not recruitingNCT06519721Not applicable
- Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCCTerminatedNCT05718882Not applicable
- IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver TransplantationStatus unknownNCT05339581Not applicable
- Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular CarcinomaCompletedNCT04642547Not applicable
- Effects of Anesthetic Methods on Hepatic Cancer Cell Function in VitroCompletedNCT04510935Not applicable
- Heterogeneity and Evolution of hepatoceLlular Carcinoma in Post-transplant HCC RecurrenceStatus unknownNCT04506398
- Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver TransplantStatus unknownNCT04425226Not applicable
- Relenvatinib in the Tatment of Recurrence of Hepatocellular Carcinoma After Liver TransplantationStatus unknownNCT04237740Phase 3
- Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular CarcinomaStatus unknownNCT04168944Phase 2/3
- Effects of Anesthetic Methods on Hepatic Cancer Cell MalignancyCompletedNCT03594188Not applicable
- CAR-GPC3 T Cells in Patients With Refractory Hepatocellular CarcinomaCompletedNCT03146234Not applicable
- Anti-GPC3 CAR T for Treating Patients With Advanced HCCCompletedNCT02395250Phase 1